CAB-AXL-ADC

Naked mAbs & Antibody Drug Conjugates

CAB-ADC antibodies aim to address the inherent limitations of current ADC antibody technology by actively binding to antigens expressed on cancer cells, but not to the same antigens expressed on normal cells in non-diseased tissues. This approach allows the preferential targeting of tumor tissues by ADCs, thereby increasing the efficacy to toxicity ratios (Therapeutic Index) of CAB-ADCs relative to their conventional counterparts. The use of CAB antibodies as payload delivery vehicles could dramatically increase the safety and number of tumor-associated antigens that are addressable with ADC technology.

Naked monoclonal antibodies or mAbs bind to specific epitopes or target molecules on cells. Therapeutic uses of mAbs have been limited by several factors, including cancer cell specificity, tumor penetration, as well as manufacturing issues. BioAtla’s human CAB mAbs are optimized and expressed in our proprietary CIAO! system. CAB mAbs have a high Therapeutic Index because they are only active under the physiological conditions associated with disease. This unique capability enables development of therapeutics for targets that are also expressed on healthy tissues, while minimizing undesirable side effects.

Representative Cancer Indications

NSCLC Breast Pancreatic Ovarian Prostate Esophageal Liver AML AXL

AXL is a receptor tyrosine kinase and oncogene involved in the stimulation of cell proliferation and associated with a variety of cancers including pancreatic, colon cancer, melanoma, CML and others. Like many cancer targets AXL is over-expressed in cancer but can also be found in some normal tissues, which would cause toxicity if treated with conventional Antibody Drug Conjugates (ADC’s). BioAtla’s CAB anti-AXL ADC however specifically targets the tumor microenvironment, reducing toxicity in normal tissue.